

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT  
Pursuant to Section 13 or 15(d) of  
the Securities Exchange Act of 1934**

Date of report (Date of earliest event reported): **June 30, 2022**

**ORAMED PHARMACEUTICALS INC.**  
(Exact name of registrant as specified in its charter)

|   |   |   |
|---|---|---|
| <b>DELAWARE</b><br>(State or Other Jurisdiction<br>of Incorporation)  | <b>001-35813</b><br>(Commission<br>File Number) | <b>98-0376008</b><br>(IRS Employer<br>Identification No.) |
| <b>1185 Avenue of the Americas, Third Floor, New York, New York</b><br>(Address of Principal Executive Offices) |   | <b>10036</b><br>(Zip Code)                                |

**844-967-2633**  
(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

| Title of each class                    | Trading symbol | Name of each exchange on which<br>registered                  |
|--|----------------|---|
| <b>Common Stock, par value \$0.012</b> | <b>ORMP</b>    | <b>The Nasdaq Capital Market,<br/>Tel Aviv Stock Exchange</b> |

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

**Item 5.07. Submission of Matters to a Vote of Security Holders.**

On June 30, 2022, Oramed Pharmaceuticals Inc. (the "Company") held its 2022 Annual Meeting of Stockholders (the "2022 Annual Meeting"). The final voting results at the 2022 Annual Meeting are set forth below.

**Proposal No. 1 — Re-election of Directors.**

The stockholders re-elected the following directors of the Company to hold office until the next annual meeting of stockholders and until their respective successors shall be elected and qualified or until their earlier resignation or removal. The votes were as follows:

| <b>Director Name</b> | <b>For</b> | <b>Against</b> | <b>Abstain</b> | <b>Broker Non-Votes</b> |
|----------------------|------------|----------------|----------------|-------------------------|
| Dr. Miriam Kidron    | 10,024,872 | 1,205,072      | 50,188         | 9,294,164               |
| Nadav Kidron         | 10,874,166 | 356,111        | 49,855         | 9,294,164               |
| Dr. Arie Mayer       | 9,749,693  | 1,468,102      | 62,337         | 9,294,164               |
| Yadin Rozov          | 10,966,776 | 247,919        | 65,437         | 9,294,164               |
| Leonard Sank         | 10,755,234 | 456,924        | 67,974         | 9,294,164               |

**Proposal No. 2 — Non-Binding Advisory Vote on the Compensation of Named Executive Officers.**

The stockholders approved, on a non-binding advisory basis, the compensation of the Company's Named Executive Officers. The votes were as follows:

| <b>For</b> | <b>Against</b> | <b>Abstain</b> | <b>Broker Non-Votes</b> |
|------------|----------------|----------------|-------------------------|
| 10,073,933 | 1,100,188      | 106,011        | 9,294,164               |

**Proposal No. 3 — Approval of an Amendment to the Company's Amended and Restated 2019 Stock Incentive Plan.**

The stockholders approved an amendment to the Company's Amended and Restated 2019 Stock Incentive Plan. The votes were as follows:

| <b>For</b> | <b>Against</b> | <b>Abstain</b> | <b>Broker Non-Votes</b> |
|------------|----------------|----------------|-------------------------|
| 5,858,015  | 4,096,378      | 1,325,739      | 9,294,164               |

**Proposal No. 4 — Ratification of Independent Registered Public Accounting Firm for the 2022 Fiscal Year.**

The stockholders ratified the appointment of Kesselman & Kesselman, certified public accountants in Israel, a member of PricewaterhouseCoopers International Limited, as the independent registered public accounting firm of the Company for the 2022 fiscal year. The votes were as follows:

| <b>For</b> | <b>Against</b> | <b>Abstain</b> | <b>Broker Non-Votes</b> |
|------------|----------------|----------------|-------------------------|
| 20,282,526 | 168,072        | 123,698        | -                       |

## **SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

### **ORAMED PHARMACEUTICALS INC.**

By: /s/ Nadav Kidron

Name: Nadav Kidron

Title: President and CEO

June 30, 2022